Search results
1 company and 41 research reports found for "vernalis"
Company results
- Vernalis
Vernalis is a UK speciality pharma company with an FDA-approved, prescription-only cough cold treatm...
Sector reports
No sector reports have been found.
Research results
-
Vernalis
Termination of coverage
Termination | Pharmaceuticals & healthcare | 21/06/2018Edison Investment Research is terminating coverage on Vernalis (VER). Please note you should no longer rely on any previous research or estimates for ...
-
Vernalis
Tuzistra XR downgrade prompts strategic rethink
Flash note | Pharmaceuticals & healthcare | 28/02/2018Vernalis has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. Despite dynamic mana...
-
Vernalis
Operational initiatives in place, execution is key
Outlook | Pharmaceuticals & healthcare | 22/11/2017Tuzistra XR prescriptions (Rx) grew threefold to ~35k in FY16/17 (2nd year on the market) vs ~12k in FY15/16. Investment into addressing the barriers ...
-
Vernalis
Tuzistra XR steady growth in Rx run rate
Update | Pharmaceuticals & healthcare | 19/07/2017Vernalis has provided a year-end trading and operational update ahead of its FY17 results due to be announced on 12 September. Total revenues are expe...
-
Vernalis
FDA issues CCP-07 complete response letter
Update | Pharmaceuticals & healthcare | 24/04/2017FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be a...
-
Vernalis
Positive Tuzistra trends
Update | Pharmaceuticals & healthcare | 15/03/2017Investment into addressing barriers to higher Tuzistra XR prescribing is starting to translate into higher prescription (Rx) rates. Mid-way through th...
-
Vernalis
Advancing towards a commercial portfolio
Update | Pharmaceuticals & healthcare | 05/01/2017FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of exte...
-
Vernalis
Investing in the commercial platform
Outlook | Pharmaceuticals & healthcare | 21/10/2016Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product f...
-
Vernalis
Cash cushion for cough cold growth
Update | Pharmaceuticals & healthcare | 25/05/2016The issue of 80m new shares at 50p/share has raised £40m (gross), which enables Vernalis to focus on executing its operational plan and removes u...
-
Vernalis
Securing cash to sustainability
Flash note | Pharmaceuticals & healthcare | 28/04/2016Vernalis intends to raise £40m (gross) through the issue of 80m new shares at 50p per share. This equity raise will remove any uncertainty over w...
-
Vernalis
Establishing a firm foundation
Update | Pharmaceuticals & healthcare | 06/04/2016Vernalis reported a modest £0.6m in Tuzistra XR sales over the first four months post-launch due to the mild cough cold season. The US launch of ...
-
Vernalis
A player in the US prescription cough cold market
Outlook | Pharmaceuticals & healthcare | 12/11/2015Vernalis is poised to complete the transition towards becoming a self-sustaining speciality pharma company, based on its five extended release cough c...
-
Vernalis
Tuzistra XR; US commercial potential unveiled
Update | Pharmaceuticals & healthcare | 17/06/2015Vernalis is preparing for commercial launch of Tuzistra XR, its extended-release, codeine-based cough cold treatment following FDA approval in April. ...
-
Vernalis
Preparing for first approval
Update | Pharmaceuticals & healthcare | 05/03/2015Vernalis represents a reduced risk late-stage pharmaceutical play, with the near-term prospect of approval in April of Tuzistra XR, an extended releas...
-
Vernalis
Aligning timings
Update | Pharmaceuticals & healthcare | 08/12/2014Vernalis’s preparations for the potential Q315 launch of Tuzistra XR, its first extended release (ER) cough cold product for the US prescription...
-
Vernalis
Daily comment
Institutional Comment | Pharmaceuticals & healthcare | 15/09/2014...
-
Vernalis
Daily comment
Institutional Comment | Pharmaceuticals & healthcare | 08/09/2014...
-
Vernalis
Cough cold portfolio gathers momentum
Outlook | Pharmaceuticals & healthcare | 08/09/2014The Tuzistra XR FDA filing is an important step towards Vernalis’s goal of profitable sustainability. Potential approval (assuming NDA acceptanc...
-
Vernalis
Getting closer to first filing
Update | Pharmaceuticals & healthcare | 14/04/2014Vernalis is well positioned to continue advancing all three elements of its business (commercial, development, research) during 2014. The first US pre...
-
Vernalis
Value proposition gathering momentum
Update | Pharmaceuticals & healthcare | 24/09/2013Vernalis’s goal of achieving sustained profitability depends on the successful development of up to six prescription-only cough cold formulation...
-
Vernalis
V81444 starts proof-of-concept study
Update | Pharmaceuticals & healthcare | 16/07/2013Vernalis has started a Phase Ib/II study for V81444, an A2A antagonist, in an unspecified CNS indication. V81444 is one of the two main unpartnered pr...
-
Vernalis
Progressing nicely
Outlook | Pharmaceuticals & healthcare | 01/05/2013Vernalis continues to progress along the path to sustained self-funding. The development of up to five prescription-only cough cold formulations is on...
-
Vernalis
First cough/cold milestone
Update | Pharmaceuticals & healthcare | 06/03/2013Vernalis has paid out its first milestone to Tris Pharma, which marks the successful “proof of concept” for the first collaboration progra...
-
Vernalis
Cough/cold portfolio on track
Outlook | Pharmaceuticals & healthcare | 10/08/2012Vernalis’s alliance with Tris Pharma to develop up to six extended release cough/cold products for the US prescription market may prove to be th...
-
Vernalis
Positioned for 2012
Update | Pharmaceuticals & healthcare | 19/04/2012Vernalis’ three-tier business strategy (commercial, development, research) has been subtly refined following the closure of its recent £65....
-
Vernalis
Worth the wait
Update | Pharmaceuticals & healthcare | 24/02/2012Vernalis’s proposed £65.9m equity raise (net of costs) and multi-product in-licensing deal with private US company Tris Pharma are the late...
-
Vernalis
Good AML data at ASH
Update | Pharmaceuticals & healthcare | 21/12/2011Promising Phase II OPAL data for oral tosedostat once-daily in elderly relapsed or refractory acute myeloid leukaemia (AML) were presented at ASH 2011...
-
Vernalis
New Frova API guidance
Update | Pharmaceuticals & healthcare | 18/11/2011Vernalis’s IMS provided new guidance on sales and delivery schedules of its sole marketed product, frovatriptan. Consequently we revise our FY11...
-
Vernalis
Reaping research rewards
Update | Pharmaceuticals & healthcare | 07/10/2011Servier and Lundbeck have paid Vernalis c £0.73m in milestones following progress under their fragment and structure-based drug discovery collabo...
-
Vernalis
The search continues
Outlook | Pharmaceuticals & healthcare | 15/08/2011Vernalis continues to focus on delivering on its three-step strategy: 1) progressing its existing pipeline, 2) expansion via in-licensing/M&A, and 3) ...
-
Vernalis
Seeking ideal deals
Review | Pharmaceuticals & healthcare | 18/04/2011Vernalis’s FY10 results provided evidence of its financial transformation, into a debt-free company with contained costs and a recurring revenu...
-
Vernalis
So FAAH, so good...
Update | Pharmaceuticals & healthcare | 21/03/2011Vernalis’s strategic focus is on in-licensing and M&A to expand its pipeline and on securing new research collaborations over the next 12 month...
-
Vernalis
The LRRK2 ascending
Update | Pharmaceuticals & healthcare | 16/12/2010Vernalis and Lundbeck have entered into a discovery collaboration that will use Vernalis’s fragment and structure-based drug discovery platform...
-
Vernalis
Awaiting acquisitions
Update | Pharmaceuticals & healthcare | 22/11/2010With £33.6m in cash at end-October, Vernalis remains well-positioned to progress and expand its R&D pipeline through licensing and acquisition. How...
-
Vernalis
Scouting for deals
Outlook | Pharmaceuticals & healthcare | 05/08/2010With £33.8m in cash, Vernalis is in a good position to progress and expand its R&D pipeline. The clinical failure of indantadol and the discontinua...
-
Vernalis
A three-step strategy
Review | Pharmaceuticals & healthcare | 14/04/2010With FY09 cash already disclosed, the focus for Vernalis’s results was the pipeline and strategic update. The recent £30m placing/reacquisit...
-
Vernalis
IN-STEP misses endpoint
Update | Pharmaceuticals & healthcare | 25/03/2010Top-line results of the IN-STEP Phase IIb trial of indantadol in diabetic neuropathic pain (DNP) missed the primary endpoint, largely due to the high ...
-
Vernalis
Fundraising and deal
Update | Pharmaceuticals & healthcare | 15/02/2010Vernalis announced the placing of £30m in new shares to fund the reacquisition of EU frovatriptan royalties from Paul Capital, and to progress it...
-
Vernalis
R&D update
Review | Pharmaceuticals & healthcare | 14/12/2009Vernaliss partner Novartis has confirmed plans to progress the HSP90 inhibitor AUY922 into a proof of concept Phase II study in 2010, an event w...
-
Vernalis
GlaxoSmithKline deal
Update | Pharmaceuticals & healthcare | 07/08/2009Vernalis has signed a licensing agreement with GlaxoSmithKline (GSK) relating to an undisclosed internally generated research target that will initial...
-
Vernalis
A new Vernalis emerges
Outlook | Pharmaceuticals & healthcare | 30/06/2009A simplified and slimmed-down business led by a new senior management team, with near-term news flow expected on clinical trials and/or partnering act...